City Vapes Premium eJuice Inc.
Letter data
- Company
- City Vapes Premium eJuice Inc.
- Recipient
- City Vapes Premium eJuice Inc. | United States | sales@cityvapes.com | doitbyecig@shaw.ca
- Issue date
- 2020-10-22
- Posted date
- Not available
- FDA office
- Center for Tobacco Products
- Subject
- Not available
- Product
- Not available
- CMS ID
- 604021
- Reference number
- RW1901231
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
City Vapes Premium eJuice Inc.
MARCS-CMS 604021 —
October 22, 2020
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA Electronic Mail
Reference #:
RW1901231
Recipient:
City Vapes Premium eJuice Inc.
United States
sales@cityvapes.com
doitbyecig@shaw.ca
Issuing Office:
Center for Tobacco Products
United States
The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions in response to our Warning Letter dated February 28, 2020. Based on our evaluation, it appears that you have taken steps to address the violation contained in the Warning Letter for the website https://cityvapes.com.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Sincerely,
/S/
David Rice
Branch Chief
Division of Promotion, Advertising, and Labeling
Office of Compliance and Enforcement
Center for Tobacco Products
Content current as of:
10/26/2020